142 related articles for article (PubMed ID: 32571680)
21. Peritoneal washing cytologic analysis of ovarian serous tumors of low malignant potential to detect peritoneal implants and predict clinical outcome.
Sneige N; Thomison JB; Malpica A; Gong Y; Ensor J; Silva EG
Cancer Cytopathol; 2012 Aug; 120(4):238-44. PubMed ID: 22826172
[TBL] [Abstract][Full Text] [Related]
22. Assessing the landscape of ovarian serous borderline tumors.
Messini I; Doulgeraki T; Chrysanthakis D; Yiannou P; Gavresea T; Papadimitriou C; Panoskaltsis T; Voulgaris Z; Vlachos A; Pavlakis K
Int J Gynecol Cancer; 2019 Mar; 29(3):572-578. PubMed ID: 30659030
[TBL] [Abstract][Full Text] [Related]
23. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
[TBL] [Abstract][Full Text] [Related]
24. Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern.
Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
BJOG; 2009 May; 116(6):860-2. PubMed ID: 19432576
[TBL] [Abstract][Full Text] [Related]
25. Ovarian serous borderline tumors with noninvasive and invasive peritoneal implants: A case report each.
Srinivasamurthy BC; Kulandai Velu AR; Krishnan N; Patil AS
J Cancer Res Ther; 2015; 11(3):646. PubMed ID: 26458602
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors.
Lazarou A; Fotopoulou C; Coumbos A; Sehouli J; Vasiljeva J; Braicu I; Burger H; Kuehn W
Anticancer Res; 2014 Nov; 34(11):6725-30. PubMed ID: 25368281
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary.
Uzan C; Muller E; Kane A; Rey A; Gouy S; Bendiffallah S; Duvillard P; Fauvet R; Darai E; Morice P
Ann Oncol; 2014 Jan; 25(1):166-71. PubMed ID: 24287939
[TBL] [Abstract][Full Text] [Related]
28. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
29. Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma.
Rollins SE; Young RH; Bell DA
Am J Surg Pathol; 2006 Apr; 30(4):457-62. PubMed ID: 16625091
[TBL] [Abstract][Full Text] [Related]
30. Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases.
Gilks CB; Alkushi A; Yue JJ; Lanvin D; Ehlen TG; Miller DM
Int J Gynecol Pathol; 2003 Jan; 22(1):29-36. PubMed ID: 12496695
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
32. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.
Seidman JD; Kurman RJ
Am J Surg Pathol; 1996 Nov; 20(11):1331-45. PubMed ID: 8898837
[TBL] [Abstract][Full Text] [Related]
33. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
[TBL] [Abstract][Full Text] [Related]
34. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
35. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary.
Uzan C; Kane A; Rey A; Gouy S; Duvillard P; Morice P
Ann Oncol; 2010 Jan; 21(1):55-60. PubMed ID: 19608617
[TBL] [Abstract][Full Text] [Related]
36. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
[TBL] [Abstract][Full Text] [Related]
37. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre.
Anfinan N; Sait K; Ghatage P; Nation J; Chu P
Arch Gynecol Obstet; 2011 Sep; 284(3):731-5. PubMed ID: 20963432
[TBL] [Abstract][Full Text] [Related]
38. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma.
Lee KR; Castrillon DH; Nucci MR
Int J Gynecol Pathol; 2001 Oct; 20(4):329-34. PubMed ID: 11603215
[TBL] [Abstract][Full Text] [Related]
39. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns.
Eichhorn JH; Bell DA; Young RH; Scully RE
Am J Surg Pathol; 1999 Apr; 23(4):397-409. PubMed ID: 10199469
[TBL] [Abstract][Full Text] [Related]
40. The Factors Predicting Recurrence in Patients With Serous Borderline Ovarian Tumor.
Ureyen I; Karalok A; Tasci T; Turkmen O; Boran N; Tulunay G; Turan T
Int J Gynecol Cancer; 2016 Jan; 26(1):66-72. PubMed ID: 26512785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
